Izencitinib induction treatment in patients with moderately-to-severely-active Crohn's Disease: A phase 2 double-blind, randomized, placebo-controlled study

被引：0
|
作者：
Schreiber, S. [1 ]
Reinisch, W. [2 ]
Nguyen, D. [3 ]
Guerin, T. [4 ]
Kierkus, J. [5 ]
Rozpondek, P. [6 ]
Bourdet, D. [3 ]
Abhyankar, B. [7 ]
Peyrin-Biroulet, L. [8 ]
机构：
[1] Univ Kiel, Univ Hosp Schleswig Holstein, Dept Internal Med I, Kiel, Germany
[2] Med Univ Vienna, Dept Internal Med III, Vienna, Austria
[3] Theravance Biopharma Inc, Res & Dev, San Francisco, CA USA
[4] Theravance Biopharma Ireland Ltd, Res & Dev, Dublin, Ireland
[5] Childrens Mem Hlth Inst, Dept Gastroenterol, Warsaw, Poland
[6] Krakow Med Ctr, Krakow, Poland
[7] Theravance Biopharma Ireland Ltd, Clin Dev, Dublin, Ireland
[8] Univ Lorraine, Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P375
引用
收藏
页码：505 / 507
页数：3
相关论文
共 50 条
  • [31] A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    Rubin, David T.
    Vermeire, Severine
    Ma, Christopher
    Ritter, Timothy
    Panaccione, Remo
    Feagan, Brian G.
    Mcgovern, Dermot P. B.
    Laurent, Olivier
    Luo, Allison
    Nguyen, Deanna D.
    Lu, J. D.
    Wiechowska-Kozlowska, Anna
    Leszczyszyn, Jaroslaw
    Kempinski, Radoslaw
    Kierkus, Jaroslaw
    Targan, Stephan
    GASTROENTEROLOGY, 2023, 164 (06) : S1570 - S1570
  • [32] No Clinical Benefit of Prebiotics in the Treatment of Active Crohn's Disease: A Double-Blind, Randomised, Placebo-Controlled Trial
    Benjamin, Jane L.
    Hedin, Charlotte R.
    Koutsoumpas, Andreas
    Ng, Siew C.
    Hart, Ailsa
    Kamm, Michael A.
    Sanderson, Jeremy D.
    Knight, Stella C.
    Forbes, Alastair
    Stagg, Andrew J.
    Whelan, Kevin
    Lindsay, James O.
    GASTROENTEROLOGY, 2010, 138 (05) : S614 - S614
  • [33] Atomoxetine for the Treatment of Depression in Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study
    Weintraub, Daniel
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 17 (03): : A67 - A67
  • [34] NO CLINICAL BENEFIT OF PREBIOTICS IN THE TREATMENT OF ACTIVE CROHN'S DISEASE: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL
    Benjamin, J. L.
    Hedin, C. R. H.
    Koutsoumpas, A.
    Ng, S. C.
    Hart, A. L.
    Kamm, M. A.
    Sanderson, J. D.
    Knight, S. C.
    Forbes, A.
    Stagg, A. J.
    Whelan, K.
    Lindsay, J. O.
    GUT, 2010, 59 : A1 - A2
  • [35] Vortioxetine Treatment for Depression in Alzheimer's Disease: A Randomized, Double-blind, Placebo-controlled Study
    Jeong, Hye Won
    Yoon, Kyung Hee
    Lee, Chang Hyun
    Moon, Yoo Sun
    Kim, Do Hoon
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (02) : 311 - 319
  • [36] A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease
    Sutherland, LR
    Martin, F
    Bailey, RJ
    Fedorak, RN
    Poleski, M
    Dallaire, C
    Rossman, R
    Saibil, F
    Lariviere, L
    Meyer, D
    Baker, SJ
    Alvi, AW
    Bass, S
    Blustein, PK
    Bridges, RJ
    Lay, TE
    vanRosendaal, GMA
    Watson, MH
    Clermont, R
    Cockeram, AW
    Mabey, M
    DaCosta, L
    Beck, IT
    Depew, W
    Groll, A
    Paterson, W
    Simon, J
    Vanner, S
    DAmore, D
    Sherbaniuk, R
    Cherry, R
    Lalor, E
    Thomson, ABR
    Yacyshyn, B
    Bain, V
    Fisher, D
    Kirdeikis, P
    Halle, P
    Irvine, EJ
    Collins, SM
    Croitoru, K
    Crowe, SE
    Goodacre, RL
    Hunt, RH
    Sabena, BJ
    Donnelly, M
    Khan, MAR
    Langevin, S
    Menard, DB
    Haddad, H
    GASTROENTEROLOGY, 1997, 112 (04) : 1069 - 1077
  • [37] Atomoxetine for the treatment of depression in Parkinson's disease: A randomized, double-blind, placebo-controlled study
    Weintraub, D.
    Mavandadi, S.
    Horn, S.
    Hurtig, H.
    Siderowf, A.
    Duda, J.
    Stern, M.
    MOVEMENT DISORDERS, 2009, 24 : S286 - S286
  • [38] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [39] Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
    Ferrante, Marc
    Panaccione, Remo
    Baert, Filip
    Bossuyt, Peter
    Colombel, Jean-Frederic
    Danese, Silvio
    Dubinsky, Marla
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lim, Allen
    Lindsay, James O.
    Loftus, Edward V., Jr.
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Ran, Zhihua
    Rubin, David T.
    Sandborn, William J.
    Schreiber, Stefan
    Neimark, Ezequiel
    Song, Alexandra
    Kligys, Kristina
    Pang, Yinuo
    Pivorunas, Valerie
    Berg, Sofie
    Duan, W. Rachel
    Huang, Bidan
    Kalabic, Jasmina
    Liao, Xiaomei
    Robinson, Anne
    Wallace, Kori
    D'Haens, Geert
    LANCET, 2022, 399 (10340): : 2031 - 2046
  • [40] A randomized, double-blind, placebo-controlled study of tetrabenazine in patients with Huntington's disease.
    Marshall, FJ
    MOVEMENT DISORDERS, 2004, 19 (09) : 1122 - 1122
12345